Literature DB >> 25335941

Amyloid imaging with [(18)F]florbetapir in geriatric depression: early-onset versus late-onset.

Amane Tateno1, Takeshi Sakayori1, Makoto Higuchi2, Tetsuya Suhara2, Keiichi Ishihara3, Shinichiro Kumita4, Hidenori Suzuki5, Yoshiro Okubo1.   

Abstract

BACKGROUND: We examined patients with mild cognitive impairment (MCI) with a history of geriatric depression (GD) and healthy controls (HC) to evaluate the effect of beta-amyloid (Aβ) pathology on the pathology of GD by using [(18)F]florbetapir PET.
METHODS: Thirty-three elderly patients (76.7 ± 4.2 years) and 22 healthy controls (HC; 72.0 ± 4.5 years, average ± SD) were examined by [(18)F]florbetapir positron emission tomography (PET) to quantify the standard uptake value ratio (SUVR) as the degree of amyloid accumulation, by MRI to determine the degree of atrophy, by Mini-Mental State Examination for cognitive functions, and by Geriatric Depression Scale for the severity of depression, and by Clinical Dementia Rating for activity of daily living (ADL). The cut-off value of 1.08 for SUVR was defined as Aβ-positive.
RESULTS: Of the patients and HC, 39.4% and 27.3%, respectively, were beta-amyloid-positive. The onset age of GD was significantly correlated with SUVR (r = 0.44, p < 0.01). Compared to patients without Aβ (GD-Aβ), patients with Aβ (GD + Aβ) did not differ in terms of age, cognitive function, severity of depression and ADL, and brain atrophy. GD + Aβ had significantly older average ± SD age at onset of GD (73.6 ± 7.1 versus 58.7 ± 17.8, p < 0.01) and significantly shorter average ± SD time between onset of GD and PET scan day (3.1 ± 5.2 years versus 18.1 ± 18.6 years, p < 0.001) than GD-Aβ.
CONCLUSIONS: Our results showed that the rate of Aβ positivity was higher in late-onset GD and that onset-age was associated with SUVR, suggesting that the later the onset of GD, the more Aβ pathology affected its onset.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Alzheimer's disease; beta-amyloid; geriatric depression; positron emission tomography

Mesh:

Substances:

Year:  2014        PMID: 25335941     DOI: 10.1002/gps.4215

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  13 in total

Review 1.  [Late-onset depression : Pathophysiology, diagnostics and treatment].

Authors:  S Notzon; J Alferink; V Arolt
Journal:  Nervenarzt       Date:  2016-09       Impact factor: 1.214

2.  Correlation between two methods of florbetapir PET quantitative analysis.

Authors:  Christopher Breault; Jonathan Piper; Abhinay D Joshi; Sara D Pirozzi; Aaron S Nelson; Ming Lu; Michael J Pontecorvo; Mark A Mintun; Michael D Devous
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-07-15

3.  Amyloid-associated depression and ApoE4 allele: longitudinal follow-up for the development of Alzheimer's disease.

Authors:  Wei Qiao Qiu; Haihao Zhu; Michael Dean; Zhiheng Liu; Linh Vu; Guanguang Fan; Huajie Li; Mkaya Mwamburi; David C Steffens; Rhoda Au
Journal:  Int J Geriatr Psychiatry       Date:  2015-08-06       Impact factor: 3.485

4.  Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study.

Authors:  Kuan-Yi Wu; Chia-Yih Liu; Cheng-Sheng Chen; Chia-Hsiang Chen; Ing-Tsung Hsiao; Chia-Ju Hsieh; Chin-Pang Lee; Tzu-Chen Yen; Kun-Ju Lin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-07       Impact factor: 9.236

Review 5.  Plasma and cerebrospinal fluid amyloid-β levels in late-life depression: A systematic review and meta-analysis.

Authors:  Kenia Kelly Fiaux do Nascimento; Kelly P Silva; Leandro F Malloy-Diniz; Meryl A Butters; Breno S Diniz
Journal:  J Psychiatr Res       Date:  2015-07-26       Impact factor: 4.791

6.  Preliminary Evidence That Cortical Amyloid Burden Predicts Poor Response to Antidepressant Medication Treatment in Cognitively Intact Individuals With Late-Life Depression.

Authors:  Warren D Taylor; Brian D Boyd; Damian Elson; Patricia Andrews; Kimberly Albert; Jennifer Vega; Paul A Newhouse; Neil D Woodward; Hakmook Kang; Sepideh Shokouhi
Journal:  Am J Geriatr Psychiatry       Date:  2020-09-28       Impact factor: 4.105

7.  Excess tau PET ligand retention in elderly patients with major depressive disorder.

Authors:  Sho Moriguchi; Keisuke Takahata; Hitoshi Shimada; Manabu Kubota; Soichiro Kitamura; Yasuyuki Kimura; Kenji Tagai; Ryosuke Tarumi; Hajime Tabuchi; Jeffrey H Meyer; Masaru Mimura; Kazunori Kawamura; Ming-Rong Zhang; Shigeo Murayama; Tetsuya Suhara; Makoto Higuchi
Journal:  Mol Psychiatry       Date:  2020-07-01       Impact factor: 15.992

8.  Beta-amyloid deposition in patients with major depressive disorder with differing levels of treatment resistance: a pilot study.

Authors:  Peng Li; Ing-Tsung Hsiao; Chia-Yih Liu; Chia-Hsiang Chen; She-Yao Huang; Tzu-Chen Yen; Kuan-Yi Wu; Kun-Ju Lin
Journal:  EJNMMI Res       Date:  2017-03-21       Impact factor: 3.138

9.  Plasma Aβ analysis using magnetically-labeled immunoassays and PET 18F-florbetapir binding in non-demented patients with major depressive disorder.

Authors:  Kuan-Yi Wu; Ing-Tsung Hsiao; Chia-Hsiang Chen; Chia-Yih Liu; Jung-Lung Hsu; Sheng-Yao Huang; Tzu-Chen Yen; Kun-Ju Lin
Journal:  Sci Rep       Date:  2018-02-09       Impact factor: 4.379

10.  A Complex Relationship Between Suicide, Dementia, and Amyloid: A Narrative Review.

Authors:  Ismael Conejero; Sophie Navucet; Jacques Keller; Emilie Olié; Philippe Courtet; Audrey Gabelle
Journal:  Front Neurosci       Date:  2018-06-01       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.